UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 1, 2012
Gevo, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware | 001-35073 | 87-0747704 | ||
(State or Other Jurisdiction of Incorporation) |
Commission File Number |
(I.R.S. Employer Identification Number) |
345 Inverness Drive South, Building C, Suite 310, Englewood, CO 80112
(Address of Principal Executive Offices) (Zip Code)
Registrants telephone number, including area code: (303) 858-8358
N/A
(Former Name, or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. | Results of Operations and Financial Condition |
On May 1, 2012, Gevo, Inc. (the Company) issued a press release announcing the Companys first quarter 2012 financial results. A copy of this press release entitled Gevo Reports First Quarter 2012 Financial Results is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. | Financial Statements and Exhibits |
(d) | Exhibits. |
99.1 | Press release, dated May 1, 2012, entitled Gevo Reports First Quarter 2012 Financial Results |
The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this report, including the exhibits hereto, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Gevo, Inc.
By: | /s/ Mark Smith | |
Mark Smith | ||
Chief Financial Officer |
Date: May 1, 2012
Exhibit 99.1
DRAFT NOT FOR RELEASE
Gevo Reports First Quarter 2012 Financial Results
Luverne, Minn. plant retrofit for commercial isobutanol production on schedule
ENGLEWOOD, Colo. May 1, 2012 Gevo, Inc. (NASDAQ: GEVO), an innovative renewable chemicals and advanced biofuels company, today announced its financial results for the three months ended March 31, 2012 and updated its expectations for isobutanol commercialization.
I am pleased to reiterate that we remain on track to start producing renewable isobutanol at our Luverne, Minn. plant by June 30 of this year, said Dr. Patrick Gruber, Chief Executive Officer. We are delivering on our most important milestone to date. Consistent with prior guidance, we anticipate the majority of our Luverne production to be shipped to Sasol Chemical Industries, Ltd. under our multi-year off-take agreement. Additionally, our co-produced Isobutanol Distillers Grains (iDGsTM) will be marketed by Land OLakes Purina Feed, LLC and we recently expanded our relationship with Land OLakes Purina Feed under a JDA to develop value-added feed applications. This is but one example of our focus on deriving value from our entire business system. Our ongoing detailed engineering of the Redfield Energy retrofit in South Dakota is progressing well as we continue to utilize insight gained from Luverne to optimize Redfields design.
On the intellectual property front, we continue to make excellent progress, added Gruber. Building on the foundational patent received in the first quarter covering our GIFT® separation system, we received three patents this quarter that cover critical technologies that enable increased isobutanol yields from our proprietary yeast. We have now received eight patents over the past eight months. We believe our engineering and yeast patents and patent applications combine to uniquely position Gevo as the leader in producing isobutanol economically and at full commercial scale.
Recent Corporate Highlights
| Gevo acquired technology developed by AmbroZea, Inc. embodied in U.S. Patent No. 7,309,602 Compositions and Methods for Producing Fermentation Products and Residuals and multiple patent applications. The acquired technology is based on modifications to yeast strains that increase the overall value of fermentation by co-producing lucrative nutrients for the animal food chain during fermentations. Gevo believes that, working in conjunction with its partner Land OLakes Purina Feed, this technology can be used to further enhance the value of iDGs. |
| Gevo and VP Racing Fuels, Inc. a world leader in race fuel technology with a diverse product catalog of high-quality specialty fuel blends, have agreed to jointly evaluate the commercial potential for |
isobutanol in a wide array of markets. The goal is to develop a product line of renewable, high-performance, isobutanol-based fuel blends for the small engine market while looking toward other performance applications for isobutanol as well. |
Additional First Quarter Highlights
| Gevo signed an off-take and marketing agreement with Land OLakes Purina Feed for the sale of iDGs produced at Gevos production facility in Luverne. Land OLakes Purina Feed will be the exclusive marketer of Gevos isobutanol dried and modified wet iDGs produced at the Luverne facility for the animal feed market. The companies solidified this relationship with a Joint Development Agreement to explore opportunities for special value-added applications in feed markets. |
| Gevo was awarded three patents for the Reduced By-Product Accumulation for Improved Production of Isobutanol, including U.S. Patent No. 8,133,715, U.S. Patent No. 8,153,415 and U.S. Patent No. 8,158,404. These patents recognize Gevos unique approach to streamlining isobutanol production in yeast. The patents cover technology that eliminates carbohydrate-hijacking pathways and improves the yield of isobutanol production. Gevo strongly believes the modifications covered by these patents are strictly required for achieving commercially relevant production of isobutanol. |
| Gevo was awarded U.S. Patent No. 8,101,808, Recovery of Higher Alcohols From Dilute Aqueous Solutions, a landmark patent on its GIFT® separation system which is a central element in Gevos unique fermentation technology for the production of isobutanol and addresses how ethanol plants can be retrofitted to produce higher alcohols. |
| Gevo was awarded U.S. Patent No. 8,097,440, Engineered Microorganisms Capable of Producing Target Compounds Under Anaerobic Conditions. The patent covers a foundational aspect of Gevos yeast technology that is designed to enable the low-cost, high-yield production of biobased isobutanol. Gevo believes the most efficient and economical way to make isobutanol through fermentation is to use yeast that is anaerobic, or doesnt need oxygen. Gevo has been awarded a patent for a novel enzyme for enabling the anaerobic production of isobutanol in yeast. |
| Gevo appointed Ruth Dreessen to its Board of Directors. Dreessen, a managing director of Lion Chemical Capital, LLC, has over 32 years of experience in chemicals and related industries. Her track record in investment banking, acquisitions and financing adds critical expertise to Gevos Board of Directors. |
Financial Highlights
Revenues for the first quarter of 2012 were $14.9 million compared to $15.3 million in the same period in 2011 reflecting an increase in grant and research and development program revenue and a decrease in ethanol sales, primarily resulting from a lower market price of ethanol during the first quarter of 2012. During the ongoing isobutanol retrofit, the Luverne facility has continued to generate revenue from the production and sale of ethanol and related products.
Research and development expense increased to $5.0 million in the first quarter of 2012 from $3.3 million for the same period in 2011. Increased investment in research and development in the first quarter of 2012 reflected increased headcount and stock-based compensation cost as well as other resources deployed in support of the ongoing retrofit of the Luverne facility.
Selling, general and administrative expense for the first quarter of 2012 increased to $13.1 million from $5.2 million for the same period in 2011. Contributing to this increase was $3.0 million in stock-based compensation expense due in part to a one-time $2.6 million non-cash expense resulting from the accelerated vesting of warrants upon the departure of two executive vice presidents. The increase also included legal-related costs including expenses in support of Gevos ongoing litigation with Butamax Advanced Biofuels, LLC, increased personnel and related expenses to support initial commercialization activities, one-time severance expense related to the departure of the two executive vice presidents and increased compliance activities as a public company.
The net loss for the first quarter of 2012 was $19.3 million compared to $9.3 million for the first quarter of 2011.
During the three months ended March 31, 2012, Gevo continued to make strides towards completing the retrofit of its Luverne plant. The Company incurred $13.3 million in retrofit related capital expenditures during the first quarter of 2012.
Gevo reported cash and cash equivalents on hand of $73.6 million as of March 31, 2012.
Webcast and Conference Call Information
Patrick R. Gruber, Ph.D., Chief Executive Officer, and Mark Smith, Chief Financial Officer, will host a conference call today at 4:30 p.m. EDT (2:30 p.m. MDT) to review the companys financial results for the three months ended March 31, 2012 and provide an update on expected isobutanol commercialization.
To participate in the conference call, please dial 1-1-866-788-0539 (inside the US) or 1-857-350-1677 (outside the US) and reference the access code 98957540. The presentation will be available via a live webcast at: http://www.media-server.com/m/acs/73e2014f48d0c44feac6ea2f1ce64bf2.
A replay of the call will be available two hours after the conference call ends on May 1, 2012 until midnight EDT on June 1, 2012. To access the replay, please dial 1-888-286-8010 (inside the US) or 1-617-801-6888 (outside the US) and reference the access code 85619628. The archived webcast will be available for 30 days in the Investor Relations section of Gevos Website at www.gevo.com.
About Gevo
Gevo is converting existing ethanol plants into biorefineries to make renewable building block products for the chemical and fuel industries. The company plans to convert renewable raw materials into isobutanol and renewable hydrocarbons that can be directly integrated on a drop in basis into existing chemical and fuel products to deliver environmental and economic benefits. Gevo is committed to a sustainable biobased economy that meets societys needs for plentiful food and clean air and water. For more information, please visit www.gevo.com.
Forward-Looking Statements
Certain statements within this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements relate to a variety of matters, including but not limited to: the timing and costs associated with and the availability of capital for Gevos scheduled retrofits of existing ethanol production facilities, its future isobutanol production capacity, the
timing associated with bringing such capacity online, the availability of additional production volumes to seed additional market opportunities, the expected applications of isobutanol, including its use to produce renewable paraxylene, PET, isobutanol-based fuel blends for use in small engines, and ATJ bio-jet, addressable markets, and market demand, Gevos ability to produce commercial quantities of isobutanol from cellulosic feedstocks, the suitability of Gevos iDGs for the animal feed market, the expected cost-competitiveness and relative performance attributes of isobutanol and the products derived from it, the strength of Gevos intellectual property position and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of Gevos management and are subject to significant risks and uncertainty. All such forward-looking statements speak only as of the date they are made, and Gevo assumes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a discussion of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see the risk disclosures in Gevos Annual Report on Form 10-K for the year ended December 31, 2011, as amended, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the Securities and Exchange Commission by Gevo.
Non-GAAP Financial Information
Consolidated financial information has been presented in accordance with GAAP as well as on a non-GAAP basis. On a non-GAAP basis, financial measures exclude non-cash items such as stock-based compensation. Management believes that it is useful to supplement its GAAP financial statements with this non-GAAP information because management uses such information internally for its operating, budgeting and financial planning purposes. These non-GAAP financial measures also facilitate managements internal comparisons to Gevos historical performance. In addition, Gevo believes these non-GAAP financial measures are useful to investors because they allow for greater transparency into the indicators used by management as a basis for its financial and operational decision making. Non-GAAP information is not prepared under a comprehensive set of accounting rules and therefore, should only be read in conjunction with financial information reported under GAAP when understanding Gevos operating performance. A reconciliation between GAAP and non-GAAP financial information is provided in the financial statement tables below.
Gevo, Inc.
Condensed Consolidated Statement of Operations
(in thousands except share and per share amounts)
Unaudited
Three Months Ended March 31, | ||||||||
2012 | 2011 | |||||||
Revenue and cost of goods sold |
||||||||
Ethanol sales and related products, net |
$ | 14,258 | $ | 15,109 | ||||
Grant revenue and research and development program revenue |
614 | 172 | ||||||
Licensing revenue |
| | ||||||
|
|
|
|
|||||
Total revenues |
14,872 | 15,281 | ||||||
|
|
|
|
|||||
Cost of goods sold |
15,010 | 15,193 | ||||||
|
|
|
|
|||||
Gross (loss) margin |
(138 | ) | 88 | |||||
|
|
|
|
|||||
Operating expenses |
||||||||
Research and development |
4,955 | 3,266 | ||||||
Selling, general and administrative |
13,127 | 5,234 | ||||||
Other operating expenses |
| | ||||||
|
|
|
|
|||||
Total operating expenses |
18,082 | 8,500 | ||||||
|
|
|
|
|||||
Loss from operations |
(18,220 | ) | (8,412 | ) | ||||
|
|
|
|
|||||
Other (expense) income |
||||||||
Interest and other expense |
(1,087 | ) | (892 | ) | ||||
Interest and other income |
| 50 | ||||||
Loss from change in fair value of warrant liabilities |
| (29 | ) | |||||
|
|
|
|
|||||
Total other expense |
(1,087 | ) | (871 | ) | ||||
|
|
|
|
|||||
Net loss |
(19,307 | ) | (9,283 | ) | ||||
Deemed dividend amortization of beneficial conversion feature on Series D-1 convertible preferred stock |
| (1,094 | ) | |||||
|
|
|
|
|||||
Net loss attributable to Gevo, Inc. common stockholders |
$ | (19,307 | ) | $ | (10,377 | ) | ||
|
|
|
|
|||||
Net loss per share attributable to Gevo, Inc. common stockholders basic and diluted |
$ | (0.74 | ) | $ | (0.76 | ) | ||
|
|
|
|
|||||
Weighted-average number of common shares outstanding basic and diluted |
26,186,133 | 13,744,337 |
Gevo, Inc.
Non-GAAP Financial Information
(in thousands)
Unaudited
Three Months Ended March 31, | ||||||||
2012 | 2011 | |||||||
Gevo Development, LLC / Agri-Energy, LLC |
||||||||
Loss from operations |
$ | (1,009 | ) | $ | (413 | ) | ||
Depreciation and amortization |
522 | 512 | ||||||
Non-cash stock-based compensation |
51 | | ||||||
|
|
|
|
|||||
Non-GAAP (loss) income from operations |
$ | (436 | ) | $ | 99 | |||
|
|
|
|
|||||
Gevo, Inc. |
||||||||
Loss from operations |
$ | (17,211 | ) | $ | (7,999 | ) | ||
Depreciation and amortization |
266 | 501 | ||||||
Non-cash stock-based compensation |
4,068 | 1,321 | ||||||
|
|
|
|
|||||
Non-GAAP loss from operations |
$ | (12,877 | ) | $ | (6,177 | ) | ||
|
|
|
|
|||||
Gevo Consolidated |
||||||||
Loss from operations |
$ | (18,220 | ) | $ | (8,412 | ) | ||
Depreciation and amortization |
788 | 1,013 | ||||||
Non-cash stock-based compensation |
4,119 | 1,321 | ||||||
|
|
|
|
|||||
Non-GAAP loss from operations |
$ | (13,313 | ) | $ | (6,078 | ) | ||
|
|
|
|
Gevo, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
Unaudited
March 31, 2012 | December 31, 2011 | |||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 73,622 | $ | 94,225 | ||||
Accounts receivable |
3,030 | 2,938 | ||||||
Inventories |
5,454 | 3,814 | ||||||
Prepaid expenses and other current assets |
2,089 | 1,757 | ||||||
|
|
|
|
|||||
Total current assets |
84,195 | 102,734 | ||||||
Property, plant and equipment, net |
42,139 | 28,777 | ||||||
Deposits and other assets |
1,641 | 1,519 | ||||||
|
|
|
|
|||||
Total assets |
$ | 127,975 | $ | 133,030 | ||||
|
|
|
|
|||||
Liabilities |
||||||||
Current liabilities: |
||||||||
Accounts payable, accrued liabilities and other current liabilities |
$ | 17,868 | $ | 12,626 | ||||
Current portion of secured debt |
6,371 | 3,491 | ||||||
|
|
|
|
|||||
Total current liabilities |
24,239 | 16,117 | ||||||
Long-term portion secured debt |
26,510 | 24,752 | ||||||
Other long-term liabilities |
18 | 24 | ||||||
|
|
|
|
|||||
Total liabilities |
50,767 | 40,893 | ||||||
|
|
|
|
|||||
Total stockholders equity |
77,208 | 92,137 | ||||||
|
|
|
|
|||||
Total liabilities and stockholders equity |
$ | 127,975 | $ | 133,030 | ||||
|
|
|
|
# # #
Jackie Kolek, Peppercom (media)
212-931-6166
jkolek@peppercom.com
Sarah McCabe, Stern Investor Relations, Inc. (investors)
212-362-1200
sarah@sternir.com
!!&O\`51Y(HGE0I(]O MJ>L<",E$Y\*L9`U5Y<:;W1^6U+EHK8:VXVY%;HLT'K+37YD=,?*?F:C&TV.T M=I:%'?=#:BPA*H-P"0*P.:>::1SX?0U[>W5A"XXCA6*6Z;$W,BDWC/DD? MD<71R)07F7LLGIR #R,(IK"TKYQRZB\&E3TS*Z-SG1O1 M'-7JKV%@QK)%.V5N`(-.9UCK+1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1T MI6(WF+]`_P`/LU]S>^^D?XAY[U=_I?VS]2]I:?1ON_ZC^]].^J?)]C\C^L?6 M?9^CX]98/-\P>3_ZF*?0^%8I\OEG-PPJV<2_X$^O)>Y^\_\`$G[/I?N'[^^[ MON#O]K%^R_Q/]I_T5]V?:?S/D?4O^8?3/E^G^C]'7(/S>4K]G_MZ\O7TYUA' MRB U_=]/0_,\^OA[OT57_ M`(GTS5+I_P#M"^V[3VGV_P#2/MKDK[@^O?=?UO[<]GD/\1_N/[E_ZG[?2_HG MS/>_T_L_;?(_H?3T/S2X]?"G_$^BUD)C/L+WFS^RO8>\^ZO^M?8^Y]?W9]NT M'_W_`,_]WWOVY]/_`)'[ORO1_P"[OUBD\U!GZ>%